Intelligent Bio Solutions (NASDAQ: INBS) back in compliance with Nasdaq $1.00 bid rule

Rhea-AI Filing Summary

Intelligent Bio Solutions Inc. reported that it has regained compliance with Nasdaq’s minimum bid price listing rule. The company previously received notice that its common stock had closed below the required $1.00 per share for 30 consecutive business days, putting its Nasdaq Capital Market listing at risk under Listing Rule 5550(a)(2).

On January 7, 2026, Nasdaq’s Listing Qualifications Staff notified the company that it is back in compliance because the closing bid price of its common stock was at or above $1.00 per share for 14 consecutive business days from December 16, 2025 to January 6, 2026. Nasdaq has indicated that the matter is now closed.

Positive

• Regained Nasdaq bid-price compliance: Nasdaq confirmed INBS met the $1.00 minimum bid price for 14 consecutive business days, closing the prior deficiency matter and removing an immediate delisting risk tied to Listing Rule 5550(a)(2).

Negative

• None.

Insights

Equity listing & market structure analyst

INBS removed an immediate Nasdaq delisting risk by regaining bid-price compliance.

Intelligent Bio Solutions Inc. had been out of compliance with Nasdaq’s minimum $1.00 bid price rule after its stock closed below that level for 30 straight business days. Such a deficiency can ultimately lead to delisting from the Nasdaq Capital Market if not cured within the grace periods, which can hurt liquidity and investor access.

Nasdaq’s letter dated January 7, 2026 confirms that the company is now back in compliance because its shares closed at or above $1.00 for 14 consecutive business days between December 16, 2025 and January 6, 2026. The Staff has stated the matter is closed, indicating no current bid-price deficiency process is ongoing.

This development stabilizes the company’s exchange listing status based on the disclosed rule. Future listing status will continue to depend on the stock maintaining criteria such as the minimum bid price required under Nasdaq Listing Rule 5550(a)(2).

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Understanding 8-K Material Events →

false 0001725430 0001725430 2026-01-07 2026-01-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): January 7, 2026

INTELLIGENT BIO SOLUTIONS INC.

(Exact name of registrant as specified in its charter)

Delaware		001-39825		82-1512711
(State of Incorporation)		(Commission File Number)		(IRS employer identification no.)

135 West 41^st Street, 5^th Floor

New York, NY 10036

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: (646) 790-5756

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.01 par value		INBS		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

As previously reported in the Current Report on Form 8-K filed by Intelligent Bio Solutions Inc. (the “Company”) on December 16, 2025, the Company received a deficiency letter (the “Bid Price Notice”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that because the closing bid price per share of the Company’s common stock was below $1.00 per share for 30 consecutive business days preceding the date of the Bid Price Notice, the Company did not meet the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”).

On January 7, 2026, the Company received a letter from the Staff notifying the Company that it had regained compliance with the Bid Price Rule as a result of the closing bid price of the Company’s common stock being at $1.00 per share or greater for the prior 14 consecutive business days (from December 16, 2025, to January 6, 2026). Accordingly, the letter indicated the Company is in compliance with the Bid Price Rule and the matter is closed.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 8, 2026
	INTELLIGENT BIO SOLUTIONS INC.
	By:	/s/ Spiro Sakiris
	Name:	Spiro Sakiris
	Title:	Chief Financial Officer

FAQ

What did Intelligent Bio Solutions Inc. (INBS) announce in this 8-K?

The company announced that Nasdaq’s Listing Qualifications Staff notified it on January 7, 2026 that it has regained compliance with the Nasdaq minimum bid price requirement under Listing Rule 5550(a)(2), and that the matter is closed.

Why was INBS previously out of compliance with Nasdaq listing rules?

Nasdaq had issued a deficiency letter because the closing bid price of INBS common stock was below $1.00 per share for 30 consecutive business days, which violated the Nasdaq Capital Market minimum bid price requirement in Listing Rule 5550(a)(2).

How did Intelligent Bio Solutions regain compliance with the Nasdaq bid price rule?

INBS regained compliance after the closing bid price of its common stock was at or above $1.00 per share for 14 consecutive business days, from December 16, 2025 to January 6, 2026, as confirmed in Nasdaq’s January 7, 2026 letter.

What does Nasdaq’s letter mean for INBS’s listing status?

Nasdaq’s letter states that INBS is in compliance with the Bid Price Rule and that the matter is closed, meaning there is no active minimum bid price deficiency proceeding based on the information disclosed.

Which Nasdaq rule is referenced in the INBS 8-K filing?

The filing references Nasdaq Listing Rule 5550(a)(2), which sets the $1.00 per share minimum bid price requirement for continued listing on the Nasdaq Capital Market.

What stock exchange is Intelligent Bio Solutions Inc. listed on?

Intelligent Bio Solutions Inc.’s common stock, par value $0.01 per share, is listed on The Nasdaq Stock Market LLC under the trading symbol INBS.